Where are we with probucol: A new life for an old drug?

Atherosclerosis

Volumn 207, Issue 1, 2009, Pages 16-23

  Yamashita, Shizuya ^a   Matsuzawa, Yuji ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SUMITOMO HOSPITAL   (Japan)

Author keywords

Anti oxidant; Atherosclerosis; Cholesteryl ester transfer protein; Coronary artery disease; Familial hypercholesterolemia; HDL cholesterol; Probucol; Risk factor

Indexed keywords

CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; CILOSTAZOL; COLESTYRAMINE; HEME OXYGENASE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN; MULTIVITAMIN; PLACEBO; PRAVASTATIN; PROBUCOL; SCAVENGER RECEPTOR;

ACUTE CORONARY SYNDROME; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CELL PROLIFERATION; CHOLESTEROL TRANSPORT; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETIC NEUROPATHY; DIET THERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; ENDOTHELIUM CELL; ENZYME INHIBITION; FAMILIAL HYPERCHOLESTEROLEMIA; HEART VENTRICLE ARRHYTHMIA; HETEROZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; INHIBITION KINETICS; JAPAN; LIPID METABOLISM; LIPOPROTEIN METABOLISM; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; RESTENOSIS; REVIEW; RISK REDUCTION; SMOOTH MUSCLE FIBER; TORSADE DES POINTES; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR ENDOTHELIUM; VASODILATATION; XANTHOMA;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; HISTORY, 20TH CENTURY; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; PROBUCOL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 70350568228     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.04.002     Document Type: Review

References (58)

1. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 366 (2005) 1267-1278
2. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
3. Graham I., Atar D., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 28 (2007) 2375-2414
4. Superko H.R., and King III S. Lipid management to reduce cardiovascular risk: a new strategy is required. Circulation 117 (2008) 560-568 [discussion 8]
5. Yamashita S., Bujo H., Arai H., et al. Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb 15 (2008) 292-303
6. Yamamoto A. A uniqe antilipidemic drug-probucol. J Atheroscler Thromb 15 (2008) 304-305
7. Sirtori C.R., and Mombelli G. Viability of developing CETP inhibitors. Cardiovas Therap 26 (2008) 135-146
8. Barnhart J.W., Sefranka J.A., and McIntosh D.D. Hypocholesterolemic effect of 4, 4′-(isopropylidenedithio)-bis (2,6-di-t-butylphenol) (probucol). Am J Clin Nutr 23 (1970) 1229-1233
9. Fruebis J., Gonzalez V., Silvestre M., and Palinski W. Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and M-CSF in the aortic wall of LDL receptor-deficient rabbits during early atherogenesis. Arterioscler Thromb Vasc Biol 17 (1997) 1289-1302
10. Brasen J.H., Koenig K., Bach H., et al. Comparison of the effects of alpha-tocopherol, ubiquinone-10 and probucol at therapeutic doses on atherosclerosis in WHHL rabbits. Atherosclerosis 163 (2002) 249-259
11. Ludmer P.L., Selwyn A.P., Shook T.L., et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 315 (1986) 1046-1051
12. Lau A.K., Leichtweis S.B., Hume P., et al. Probucol promotes functional reendothelialization in balloon-injured rabbit aortas. Circulation 107 (2003) 2031-2036
13. Witting P.K., Wu B.J., Raftery M., Southwell-Keely P., and Stocker R. Probucol protects against hypochlorite-induced endothelial dysfunction. Identification of a novel pathway of probucol oxidation to a biologically active intermediate. J Biol Chem 280 (2005) 15612-15618
14. Wu B.J., Kathir K., Witting P.K., et al. Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging. J Exp Med 203 (2006) 1117-1127
15. Alam J., Stewart D., Touchard C., et al. Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene. J Biol Chem 274 (1999) 26071-26078
16. Kita T., Nagano Y., Yokode M., et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 84 (1987) 5928-5931
17. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., and Witztum J.L. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320 (1989) 915-924
18. Sasahara M., Raines E.W., Chait A., et al. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation?. J Clin Invest 94 (1994) 155-164
19. Stocker R., and Keaney Jr. J.F. Role of oxidative modifications in atherosclerosis. Physiol Rev 84 (2004) 1381-1478
20. Witting P.K., Pettersson K., Ostlund-Lindqvist A.-M., et al. Dissociation of atherogenesis from aortic accumulation of lipid hydro(per)oxides in Watanabe heritable hyperlipidemic rabbits. J Clin Invest 104 (1999) 213-220
21. Franceschini G., Sirtori M., Vaccarino V., et al. Mechanisms of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer. Arteriosclerosis 9 (1989) 462-469
22. Ishigami M., Yamashita S., Sakai N., et al. High-density lipoproteins from probucol-treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins. Eur J Clin Invest 27 (1997) 285-292
23. Hirano K., Ikegami C., Tsujii K., et al. Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism. Arterioscler Thromb Vasc Biol 25 (2005) 2422-2427
24. Miida T., Seino U., Miyazaki O., et al. Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alpha-migrating HDL: putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling. Atherosclerosis 200 (2008) 329-335
25. Favari E., Zanotti I., Zimetti F., et al. Probucol inhibits ABCA1-mediated cellular lipid efflux. Arterioscler Thromb Vasc Biol 24 (2004) 2345-2350
26. Moghadasian M.H. Dietary phytosterols reduce probucol-induced atherogenesis in apo E-KO mice. Atherosclerosis 188 (2006) 28-34
27. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007) 2109-2122
28. Hirano K., Yamashita S., Nakajima N., et al. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol 17 (1997) 1053-1059
29. Nagano M., Yamashita S., Hirano K., et al. Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese. J Atheroscler Thromb 11 (2004) 110-121
30. Matsuzawa Y., Yamashita S., Kameda K., et al. Marked hyper-HDL2-cholesterolemia associated with premature corneal opacity. A case report. Atherosclerosis 53 (1984) 207-212
31. Cazita P.M., Barbeiro D.F., Moretti A.I., Quintão E.C., and Soriano F.G. Human cholesteryl ester transfer protein expression enhances the mouse survival rate in an experimental systemic inflammation model: a novel role for CETP. Shock 30 (2008) 590-595
32. Thompson J.F., Reynolds J.M., Williams S.P., et al. Frequency and function of CETP variants among individuals of Asian ancestry. Atherosclerosis 202 (2009) 241-247
33. Braun A., Zhang S., Miettinen H.E., et al. Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI/apolipoprotein E double knockout mouse. Proc Natl Acad Sci USA 100 (2003) 7283-7288
34. Ferns G.A., Forster L., Stewart-Lee A., et al. Probucol inhibits neointimal thickening and macrophage accumulation after balloon injury in the cholesterol-fed rabbit. Proc Natl Acad Sci USA 89 (1992) 11312-11316
35. Tanaka K., Hayashi K., Shingu T., et al. Probucol inhibits neointimal formation in carotid arteries of normocholesterolemic rabbits and the proliferation of cultured rabbit vascular smooth muscle cells. Cardiovasc Drugs Ther 12 (1998) 19-28
36. Yang Y.B., Yang Y.X., Su B., et al. Probucol mediates vascular remodeling after percutaneous transluminal angioplasty via down-regulation of the ERK1/2 signaling pathway. Eur J Pharmacol 570 (2007) 125-134
37. Wu B.J., Di Girolamo N., Beck K., et al. Probucol[4,4′-[(1-methylethylidene)bis(thio)]bis-[2,6-bis(1,1-dimethylethyl)phenol]] inhibits compensatory remodeling and promotes lumen loss associated with atherosclerosis in apolipoprotein E-deficient mice. J Pharmacol Exp Ther 321 (2007) 477-484
38. Sekiya M., Funada J., Watanabe K., Miyagawa M., and Akutsu H. Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am J Cardiol 82 (1998) 144-147
39. Park S.Y., Lee J.H., Kim C.D., et al. Beneficial synergistic effects of concurrent treatment with cilostazol and probucol against focal cerebral ischemic injury in rats. Brain Res 1157 (2007) 112-120
40. Yoshikawa T., Mitani K., Kotosai K., et al. Antiatherogenic effects of cilostazol and probucol alone, and in combination in low density lipoprotein receptor-deficient mice fed with a high fat diet. Horm Metab Res 40 (2008) 473-478
41. Umehara K., Shimokawa Y., and Miyamoto G. Effect of probucol on cytochrome P450 activities in human liver microsomes. Biol Pharm Bull 25 (2002) 1112-1114
42. Matsuzawa Y., Yamashita S., Funahashi T., Yamamoto A., and Tarui S. Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer. Am J Cardiol 62 (1988) 66B-72B
43. Yamamoto A., Hara H., Takaichi S., Wakasugi J., and Tomikawa M. Effect of probucol on macrophages, leading to regression of xanthomas and atheromatous vascular lesions. Am J Cardiol 62 (1988) 31B-36B
44. Nakamura T., Ueyama Y., Funahashi T., et al. Non-macrophage-related accumulation of cholesterol during probucol treatment in familial hypercholesterolemia: report of two cases. Atherosclerosis 92 (1992) 193-202
45. Walldius G., Erikson U., Olsson A.G., et al. The effect of probucol on femoral Atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 74 (1994) 875-883
46. Tardif J.C., Cote G., Lesperance J., et al. Impact of residual plaque burden after balloon angioplasty in the MultiVitamins and Probucol (MVP) trial. Can J Cardiol 17 (2001) 49-55
47. Sawayama Y., Shimizu C., Maeda N., et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 39 (2002) 610-616
48. Tardif J.C., Gregoire J., Schwartz L., et al. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 107 (2003) 552-558
49. Tardif J.C., McMurray J.J., Klug E., et al. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 371 (2008) 1761-1768
50. Viskin S., Justo D., Halkin A., and Zeltser D. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis 45 (2003) 415-427
51. Guo J., Massaeli H., Li W., et al. Identification of IKr and its trafficking disruption induced by probucol in cultured neonatal rat cardiomyocytes. J Pharmacol Exp Ther 321 (2007) 911-920
52. Tamura M., Ueki Y., Ohtsuka E., et al. Probucol-induced QT prolongation and syncope. Jpn Circ J 58 (1994) 374-377
53. Arai T., Wang N., Bezouevski M., et al. Decrease atherosclerosis on heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. J Biol Chem 274 (1999) 2366-2371
54. Yokoi H., Daida T., Kuwabara Y., et al. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: The Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol 30 (1997) 855-862
55. Tardif J.C., Cote G., Lesperance J., et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. NEJM 337 (1997) 365-372
56. Gallino A., Do D.D., Alerci M., et al. Effects of probucol versus aspirin and versu brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. J Endvasc Ther 11 (2004) 595-604
57. Endo K., Miyashita Y., Sasaki H., et al. Probucol delays progression of diabetic nephropathy. Diabetes Res Clin Pract 71 (2006) 156-163
58. Tardif J.C., McMurray J.J.V., Klug E., et al. Effects of succinobucol(AGI-1067) after an acute coronary syndrome: a randomized, double-blind, placebo-controlled trial. Lancet 371 (2008) 1761-1768